pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 29·1 min read
save

Study finds clinical chatbots lag behind general AI models in accuracy, sparking debate among doctors

Jul 29, 2026·read at STAT ↗Negative readoutNegative

Hundreds of thousands of U.S. physicians are using clinical large language model tools marketed by firms such as OpenEvidence, Doximity and UpToDate as safer alternatives to generic AI chatbots.

A research team from NYU Langone Health evaluated both general purpose and clinical focused models on three sets of medical questions, and the results were published in Nature Medicine in June.

The study showed the clinical specific AI performed worse than the general models, a finding that surprised many and prompted a strong reaction on social media, including a comment from Kaiser Permanente's vice president of AI.

Developers of the clinical tools argue that current benchmarking methods do not accurately capture safety and usefulness, highlighting ongoing debate over how to assess AI in healthcare.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Clinical chatbots are taking medicine by storm. Should doctors trust them?”

read at STAT ↗
521 words · retrieved Jul 29
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Type 2 Diabetes

related stories

  • May 11Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trialBioPharma Dive
  • May 8Trump reportedly plans to fire FDA Commissioner MakarySTAT
  • May 8Lilly to invest extra $4.5B across Indiana manufacturingBioPharma Dive
  • May 8Lilly, Gilead lead pharma’s M&A boomBioPharma Dive
  • May 7Official leading CDC’s cruise ship program retiresSTAT